Business · 30/03/2023
GlaxoSmithKline Requests Revocation of Biologics License for BLENREP
GlaxoSmithKline has requested the FDA to revoke the biologics license for BLENREP, a treatment for certain types of cancer, after waiving its right to a hearing, effectively ending its use in the US market.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →